Xanthopsia (drug‑induced visual change) - Causes, Treatment & When to See a Doctor

```html

What is Xanthopsia (drug‑induced visual change)?

Xanthopsia is a type of dyschromatopsia in which objects appear tinted yellow‑or amber. When it is caused by medications, it is referred to as drug‑induced xanthopsia. The condition is usually reversible once the offending drug is discontinued or its dose is adjusted, but the visual distortion can be unsettling and may interfere with daily activities such as reading, driving, or operating machinery.

The word comes from Greek — “xanthos” (yellow) and “opsis” (vision). Unlike a permanent retinal disease, drug‑induced xanthopsia is a functional change in the way the brain processes colour information, often related to the drug’s effect on retinal photoreceptors, neural pathways, or the brain’s visual cortex.

Common Causes

The majority of cases are linked to medications that alter the eye’s chemistry or affect the central nervous system. Below are the most frequently reported culprits (each supported by case reports or pharmacovigilance data):

• Digitalis glycosides (e.g., digoxin, digitoxin) – classic cause, especially at therapeutic or toxic levels.
• Topiramate – an anticonvulsant that can cause visual field defects and colour distortion.
• Phosphodiesterase‑5 inhibitors (e.g., sildenafil, tadalafil) – rare reports of yellow‑hued vision.
• Phenothiazine antipsychotics (e.g., chlorpromazine, thioridazine) – can affect retinal pigment epithelium.
• Quinine and related antimalarials – known for visual disturbances, including xanthopsia.
• Corticosteroids (systemic or high‑dose topical) – may alter retinal metabolism.
• Isotretinoin (Accutane) – retinoid therapy occasionally produces colour‑vision changes.
• Amiodarone – an anti‑arrhythmic that can deposit in the cornea and retina.
• Chloroquine/Hydroxychloroquine – long‑term use can cause retinal toxicity and colour shifts.
• Certain chemotherapeutic agents (e.g., vincristine, cisplatin) – neuro‑ophthalmic side effects may include xanthopsia.

Associated Symptoms

While the hallmark of xanthopsia is a yellow tint, patients often report other visual or systemic clues that help clinicians pinpoint the cause:

• Blurring or decreased visual acuity.
• Glare or halos around lights, especially at night.
• Difficulty distinguishing reds from greens (mixed dyschromatopsia).
• Photophobia (light sensitivity).
• Peripheral visual field loss or scotomas (particularly with topiramate or phosphodiesterase‑5 inhibitors).
• Headache, nausea, or dizziness – suggestive of systemic toxicity (e.g., digoxin).
• Skin yellowing (jaundice) when the underlying cause is hepatic dysfunction rather than a drug.
• Dry eyes or foreign‑body sensation if corneal deposition is present (amiodarone, chloroquine).

When to See a Doctor

Because many of the implicated drugs are essential for treating serious conditions, it is important to balance benefits and risks. Seek medical evaluation promptly if you experience any of the following:

• Sudden onset of yellow‑tinged vision that does not improve within 24–48 hours.
• Vision loss, double vision, or new blind spots.
• Severe headache, palpitations, confusion, or fainting (possible digoxin toxicity).
• Persistent glare or difficulty driving at night.
• Any visual change while on a new medication or after a dose increase.
• Symptoms of an allergic reaction (rash, swelling, difficulty breathing) – may coincide with drug‑induced ocular toxicity.

Early assessment can prevent permanent retinal damage and allow safe adjustment of therapy.

Diagnosis

Diagnosing drug‑induced xanthopsia involves a combination of patient history, focused eye examination, and targeted investigations:

1. Detailed Medication Review

Clinicians ask for a complete list of prescription, over‑the‑counter, herbal, and dietary supplements. Timing of symptom onset relative to drug initiation is a key clue.

2. Visual‑Function Tests

• Colour Vision Testing – Ishihara plates, Farnsworth‑Munsell 100‑Hue test, or Cone Contrast Test to quantify the yellow shift.
• Visual Acuity – Standard Snellen or ETDRS charts.
• Contrast Sensitivity – Assess how well the patient can detect low‑contrast objects.

3. Ophthalmic Imaging

• Optical Coherence Tomography (OCT) – Detects subtle retinal layer changes, especially in chloroquine/hydroxychloroquine toxicity.
• Fundus Autofluorescence – Highlights retinal pigment epithelium stress.
• Fluorescein Angiography – Rarely needed but useful if vascular abnormalities are suspected.

4. Laboratory Tests (if systemic toxicity suspected)

• Serum digoxin level.
• Liver function tests (for drugs metabolised hepatically).
• Renal panel (important for drugs cleared renally).
• Electrolytes – especially potassium for digoxin toxicity.

5. Differential Diagnosis

Clinicians rule out other causes of yellow vision such as jaundice, cataract, macular degeneration, optic neuritis, or neurological lesions.

Treatment Options

Because the underlying mechanism is drug‑related, the primary strategy is to modify the offending agent. Adjunctive measures can speed recovery and protect retinal health.

1. Medication Management

• Discontinue or substitute the drug – e.g., switch from digoxin to an alternative rate‑control agent.
• Dose reduction – lowering the dose may resolve visual changes while maintaining therapeutic effect.
• Therapeutic drug monitoring – especially for digoxin, lithium, or anti‑epileptics.

2. Symptomatic Relief

• Artificial tears for dry‑eye symptoms.
• Prescription sunglasses with yellow‑tint filters can paradoxically reduce glare for some patients.
• Adaptive devices (large‑print reading material, high‑contrast screen settings).

3. Retinal Protective Therapies (where evidence supports)

• Hydroxychloroquine toxicity – immediate cessation; early retinal changes may be partially reversible.
• Amiodarone‑induced corneal deposits – dose reduction; deposits often clear after stopping the drug.

4. Follow‑up Care

Schedule repeat colour‑vision testing and OCT 4–6 weeks after drug modification to confirm improvement. Persistent changes may warrant referral to a retinal specialist.

Prevention Tips

• Inform your eye doctor of all medications, including supplements.
• Ask your prescribing physician about known ocular side effects before starting a new drug.
• Adhere strictly to prescribed doses; never double‑dose to compensate for missed pills.
• For high‑risk drugs (digoxin, hydroxychloroquine), attend regular monitoring appointments.
• Protect eyes from excessive UV exposure – wear sunglasses with proper UV protection.
• Maintain good overall health (adequate hydration, balanced diet rich in lutein/zeaxanthin) to support retinal resilience.
• Report any visual change to a healthcare professional within 24 hours.

Emergency Warning Signs

---

**Sources**: Mayo Clinic, National Institutes of Health (NIH) – MedlinePlus, Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), Cleveland Clinic, peer‑reviewed articles in Ophthalmology and Drug Safety journals (2021‑2024).

```